J.Jpn. Surg. Soc.. 60(11): 1785-1803, 1960
EXPERIMENTAL STUDY ON THE ADMINISTRATION OF ANTICANCER DRTGS.
-ON THE CONTINOUS ADMINISTRATION OF NITROMIN (NMO)-
|
1st Smugical Department, Tokyo University School of Medicine (Director: Prof. Kentaro SHIMIZU) Masami ARAI |
NMO of various doses and various concentrations were given intraperiteneally to the Yoshida Sarcoma-bearing-rats, and the staying times of NMO in the peritoneal cavity were measured by the same method.
2) NMO was given to the Yoshida Sarcoma-bearing-rats intravenously or orally.
MED of NMO was 0.25 mg/kg, 0.5 mg/kg respectively.
3) The effects of NMO were studied in various groups changing the concentration and the contact time with the Yoshida Sarcoma cells.
i. ) The time-factor had greater role for the NM- effects than the concentrationfactor when the in vitro-in vivo method was used.
ii. ) The life prolongation effects were observed, when the same total dosis of NMO was given intraperitoneally to the Yoshida Sarcoma-bearing-rats by the various methods.
When the continous administration is used, NMO acts on the Yoshida Sarcoma cells during its one generation time, so it is expected that this administration is capable of destruction of all Yoshida Sarcoma cells.
All of the Yoshida Sarcoma-bearing-rats were cured by this ontinous administrations. This result obtained by the continous administration was far excellent than that of the other administrations.
iii.) The liver catalase activities of the Yoshida Sarcoma-bearing-rats and the healthy rats were measured, when the various intraperitoneal administrations of NMO were used.
There were no differences in the liver catalase activities of the each groups of the rats.
4) The influences of the continous administration of NMO upon the peripheral leucocytes counts, the body weights, and the resistence or Yoshida Sarcoma of the healthy rats were more slightly rather than the other administrations.
5) There were no differ ences in the grade of the NMO-resistency of Yoshida Sarcoma which were acquired during the various intraperitonel administrations of NMO.
(Author's abstract)
To read the PDF file you will need Adobe Reader installed on your computer.